Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at firstname.lastname@example.org.
Lacerta Bio is pleased to return to Europe for the 20th Anniversary of the BIO-Europe conference.
We will be there from Sunday evening through Wednesday afternoon.
Look for us in PartneringOne, or contact us at email@example.com to schedule a meeting with us.
You can also follow the action on Twitter via the #BEU14 hashtag.
We’re actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: – Is currently involved in business development and licensing - Currently works for a pharma, biotech, VC, PE, or consultancy - Is able to write 500+ word articles related to business development and licensing The key is to have high quality, original, insightful Read More »
This morning we learned that Sanofi is the winner in the “Where on Earth is the Partner for Afrezza?” sweepstakes. We’ll defer to the many news outlets for the details. But one interesting take on the deal is from TheStreet.com. A few good points were raised: Sanofi advanced $175 MM to MannKind as Read More »
Yes, and it might be worth it. Yesterday, Daiichi Sankyo announced an incredible $650 million deal with Florida-based Charleston Laboratories for the development and commercialization of a family of fixed dose combination products. The lead candidate, CL-108, is a fixed dose combination of promethazine, hydrocodone, and acetaminophen. The deal was signed on the back of Read More »